12.35
-0.2(-1.59%)
Currency In USD
| Previous Close | 12.55 |
| Open | 12.6 |
| Day High | 12.6 |
| Day Low | 11.8 |
| 52-Week High | 14.93 |
| 52-Week Low | 3.9 |
| Volume | 788,598 |
| Average Volume | 1.24M |
| Market Cap | 1.2B |
| PE | -6.53 |
| EPS | -1.89 |
| Moving Average 50 Days | 12.01 |
| Moving Average 200 Days | 9.24 |
| Change | -0.2 |
If you invested $1000 in ORIC Pharmaceuticals, Inc. (ORIC) since IPO date, it would be worth $479.24 as of November 08, 2025 at a share price of $12.35. Whereas If you bought $1000 worth of ORIC Pharmaceuticals, Inc. (ORIC) shares 3 years ago, it would be worth $4,881.42 as of November 08, 2025 at a share price of $12.35.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
ORIC® Pharmaceuticals Presented Preclinical Data at the EORTC-NCI-AACR International Conference on Molecular Targets and Cancer Therapeutics Supporting Best-in-Class Potential of ORIC-944 to Treat Patients With Prostate Cancer and Other Solid Tumors
GlobeNewswire Inc.
Oct 27, 2025 12:30 PM GMT
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, presented
ORIC® Pharmaceuticals Expands Leadership Team with the Appointment of Kevin Brodbeck as Chief Technical Officer
GlobeNewswire Inc.
Aug 18, 2025 8:05 PM GMT
SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today anno
ORIC® Pharmaceuticals Announces Potentially Best-In-Class Preliminary Efficacy and Safety Data from Ongoing Phase 1b Trial of ORIC-944 in Combination with AR Inhibitors for the Treatment of Patients with mCRPC
GlobeNewswire Inc.
May 28, 2025 8:05 PM GMT
Broad and deep PSA responses achieved, with 59% PSA50 response rate (confirmed rate of 47%, and one additional response pending confirmation) and 24% PSA90 response rate (all confirmed) in patients with mCRPC PSA responses were observed across